Share-Based Compensation (Tables)

3 Months Ended

Sep. 30, 2014

Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding

A summary of the stock option activity under the Company’s plans for the three months ended September 30, 2014 is as follows:


			Weighted
	Number		average
	of		exercise
	shares		price
Options outstanding at June 30, 2014		14,238,603	$	23.30
Options granted		1,000		37.17
Less:
Options exercised		705,944		21.39
Options canceled or expired		83,785		24.41

Options outstanding at September 30, 2014		13,449,874	$	23.39

Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Outstanding

A summary of the RSU activity under the Company’s plans for the three months ended September 30, 2014 is as follows:


	Number		Weighted
	of		average grant
	shares		date fair value
RSUs outstanding at June 30, 2014		—	$	—
RSUs granted		1,085,733		38.12
Less:
RSUs vested		—		—
RSUs canceled		3,200		38.12

RSUs outstanding at September 30, 2014		1,082,533	$	38.12

Schedule of Share-Based Compensation Recognized in Consolidated Statements of Income and Comprehensive Income

Share-based compensation expense recognized and included in the condensed consolidated statements of income and comprehensive income was allocated as follows:


	Three months ended
	September 30,
(In thousands)	2014		2013
Cost of molecular diagnostic testing	$	198	$	223
Cost of pharmaceutical and clinical services		160		62
Research and development expense		764		782
Selling, general, and administrative expense		5,758		5,868

Total share-based compensation expense	$	6,880	$	6,935